LifeSci Capital's second healthcare SPAC Lifesci Acquisition II files for a $75 million IPO
Lifesci Acquisition II, the second blank check company formed by LifeSci Capital targeting the healthcare industry, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering.
The New York, NY-based company plans to raise $75 million by offering 7.5 million shares at $10. Unlike an ordinary SPAC, the company is not offering warrants that would become exercisable following completion of the initial business combination. At the proposed deal size, Lifesci Acquisition II would command a market value of $94 million.
The company is led by CEO and Chairman Andrew McDonald and COO and Director Michael Rice, who are Founding Partners at healthcare-dedicated investment bank LifeSci Capital. CFO and Director David Dobkin is currently a Managing Director at LifeSci Capital. The SPAC plans to target the biopharma, medical technology, digital health, and healthcare services sectors in North America or Europe.
LifeSci Capital's previous SPAC, LifeSci Acquisition (LSAC; +34% from $10 offer price), went public in March 2020 and recently announced a merger agreement with oncology biotech Vincera Pharma.
Lifesci Acquisition II was founded in 2019 and plans to list on the Nasdaq under the symbol LSAQ. LifeSci Capital is the sole bookrunner on the deal.
The article LifeSci Capital's second healthcare SPAC Lifesci Acquisition II files for a $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.